Adverse effects įrequency of adverse effects: ĭesvenlafaxine improves the HAM-D17 score and measures of well being such as the Sheehan Disability Scale (SDS) and 5-item World Health Organization Well-Being Index (WHO-5). ĭoses of 50–400 mg/day appear effective for major depressive disorder, although no additional benefit was demonstrated at doses greater than 50 mg/day, and adverse events and discontinuations were more frequent at higher doses. It may be less effective than venlafaxine, although some studies have found comparable efficacy with a lower rate of nausea. ĭesvenlafaxine is primarily used as a treatment for major depressive disorder. In 2019, it was the 177th most commonly prescribed medication in the United States, with more than 3 million prescriptions. In Europe its application for use was denied in 2009. ĭesvenlafaxine was approved for medical use in the United States in 2008.

It is unclear if use during pregnancy or breastfeeding is safe. A withdrawal syndrome may occur if the dose is rapidly decreased. Serious side effects may include suicide in those under the age of 25, serotonin syndrome, bleeding, mania, and high blood pressure.

Ĭommon side effects include dizziness, trouble sleeping, increased sweating, constipation, sleepiness, anxiety, and sexual problems. It is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class and is taken by mouth. It may be less effective than its parent compound venlafaxine, although some studies have found comparable efficacy. It is recommended that the need for further treatment be occasionally reassessed. Desvenlafaxine, sold under the brand name Pristiq among others, is a medication used to treat depression.

Desvenlafaxine succinate er